J Korean Med Assoc.  2017 May;60(5):409-416. 10.5124/jkma.2017.60.5.409.

Pharmacologic treatment of seborrheic dermatitis

• Hur MS
• Lee YW

• KMID: 2378973
• DOI: http://doi.org/10.5124/jkma.2017.60.5.409

Abstract

Seborrheic dermatitis is a chronic, recurrent papulosquamous skin disorder characterized by flaking of the skin, erythema, pruritus, and oily skin. It is a common dermatosis, with a prevalence of approximately 1% to 3% of the general population in the United States. The incidence of this skin disease has a bimodal distribution, with peaks noted in newborns and in adults between 30 and 60 years of age. In adults, it predominantly occurs over areas of the body with a high concentration of sebaceous glands. The etiology of this disease is thought to be an inflammatory response of the body to Malassezia yeasts. It is also related to abnormal sebum secretion, as well as a heightened immune response of the host. Based on the characteristic features of this inflammatory skin disease, the mainstays of treatment for seborrheic dermatitis are antifungals, corticosteroids, and immunomodulatory agents. The primary goal of therapy for seborrheic dermatitis is to manage acute symptoms, including pruritus, erythema, and scaling. Maintenance treatment is directed toward preventing the recurrence of acute exacerbations. Patients should be informed that seborrheic dermatitis is a chronic condition, with a tendency to recur despite proper treatment. Clinicians should offer suggestions about lifestyle modifications to avoid triggers and choose proper treatment options that ensure the patient's safety.

Keyword

Dandruff; Dermatitis, seborrheic; Therapeutics

MeSH Terms

Adrenal Cortex Hormones
Adult
Dandruff
Dermatitis, Seborrheic*
Erythema
Humans
Incidence
Infant, Newborn
Life Style
Malassezia
Prevalence
Pruritus
Recurrence
Sebaceous Glands
Sebum
Skin
Skin Diseases
United States
Yeasts
Adrenal Cortex Hormones

Reference

1. Schwartz RA, Janusz CA, Janniger CK. Seborrheic dermatitis: an overview. Am Fam Physician. 2006; 74:125–130.

2. Schwartz JR, Messenger AG, Tosti A, Todd G, Hordinsky M, Hay RJ, Wang X, Zachariae C, Kerr KM, Henry JP, Rust RC, Robinson MK. A comprehensive pathophysiology of dandruff and seborrheic dermatitis: towards a more precise definition of scalp health. Acta Derm Venereol. 2013; 93:131–137.

3. Lee YW, Yim SM, Lim SH, Choe YB, Ahn KJ. Quantitative investigation on the distribution of Malassezia species on healthy human skin in Korea. Mycoses. 2006; 49:405–410.

4. Faergemann J, Johansson S, Back O, Scheynius A. An immunologic and cultural study of Pityrosporum folliculitis. J Am Acad Dermatol. 1986; 14:429–433.

5. Mayer-da-Silva A, Gollnick H, Detmar M, Gassmüller J, Parry A, Muller R, Orfanos CE. Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin: an in vivo and in vitro study. Acta Derm Venereol Suppl (Stockh). 1989; 143:20–30.

6. Peyri J, Lleonart M. Grupo espanol del Estudio SEBDERM. Clinical and therapeutic profile and quality of life of patients with seborrheic dermatitis. Actas Dermosifiliogr. 2007; 98:476–482.

7. Nicolas V, Nefussi JR, Collin P, Forest N. Effects of acidic fibroblast growth factor and epidermal growth factor on subconfluent fetal rat calvaria cell cultures: DNA synthesis and alkaline phosphatase activity. Bone Miner. 1990; 8:145–156.

8. Nenoff P, Haustein UF, Fiedler A. The antifungal activity of a coal tar gel on Malassezia furfur in vitro. Dermatology. 1995; 191:311–314.

9. Shuster S. The aetiology of dandruff and the mode of action of therapeutic agents. Br J Dermatol. 1984; 111:235–242.

10. Danby FW, Maddin WS, Margesson LJ, Rosenthal D. A randomized, double-blind, placebo-controlled trial of ketoconazole 2% shampoo versus selenium sulfide 2.5% shampoo in the treatment of moderate to severe dandruff. J Am Acad Dermatol. 1993; 29:1008–1012.

11. Rapaport M. A randomized, controlled clinical trial of four anti-dandruff shampoos. J Int Med Res. 1981; 9:152–156.

12. Mills KJ, Hu P, Henry J, Tamura M, Tiesman JP, Xu J. Dandruff/seborrhoeic dermatitis is characterized by an inflammatory genomic signature and possible immune dysfunction: transcriptional analysis of the condition and treatment effects of zinc pyrithione. Br J Dermatol. 2012; 166:Suppl 2. 33–40.

13. Warner RR, Schwartz JR, Boissy Y, Dawson TL Jr. Dandruff has an altered stratum corneum ultrastructure that is improved with zinc pyrithione shampoo. J Am Acad Dermatol. 2001; 45:897–903.

14. Nenoff P, Haustein UF, Brandt W. Antifungal activity of the essential oil of Melaleuca alternifolia (tea tree oil) against pathogenic fungi in vitro. Skin Pharmacol. 1996; 9:388–394.

15. Homeyer DC, Sanchez CJ, Mende K, Beckius ML, Murray CK, Wenke JC, Akers KS. In vitro activity of Melaleuca alternifolia (tea tree) oil on filamentous fungi and toxicity to human cells. Med Mycol. 2015; 53:285–294.

16. Pazyar N, Yaghoobi R, Bagherani N, Kazerouni A. A review of applications of tea tree oil in dermatology. Int J Dermatol. 2013; 52:784–790.

17. Satchell AC, Saurajen A, Bell C, Barnetson RS. Treatment of dandruff with 5% tea tree oil shampoo. J Am Acad Dermatol. 2002; 47:852–855.

18. Van Cutsem J, Van Gerven F, Cauwenbergh G, Odds F, Janssen PA. The antiinflammatory effects of ketoconazole: a comparative study with hydrocortisone acetate in a model using living and killed Staphylococcus aureus on the skin of guinea-pigs. J Am Acad Dermatol. 1991; 25(2 Pt 1):257–261.

19. Pierard-Franchimont C, Hermanns JF, Degreef H, Pierard GE. From axioms to new insights into dandruff. Dermatology. 2000; 200:93–98.

20. Gupta AK, Nicol K, Batra R. Role of antifungal agents in the treatment of seborrheic dermatitis. Am J Clin Dermatol. 2004; 5:417–422.

21. Lassus A, Nolting KS, Savopoulos C. Comparison of ciclopirox olamine 1% cream with ciclopirox 1%-hydrocortisone acetate 1% cream in the treatment of inflamed superficial mycoses. Clin Ther. 1988; 10:594–599.

22. Altmeyer P, Hoffmann K. Loprox Shampoo Dosing Concentration Study Group. Efficacy of different concentrations of ciclopirox shampoo for the treatment of seborrheic dermatitis of the scalp: results of a randomized, double-blind, vehicle-controlled trial. Int J Dermatol. 2004; 43:Suppl 1. 9–12.

23. Lee JH, Lee HS, Eun HC, Cho KH. Successful treatment of dandruff with 1.5% ciclopirox olamine shampoo in Korea. J Dermatolog Treat. 2003; 14:212–215.

24. Poulin Y, Papp K, Bissonnette R, Guenther L, Tan J, Lynde C, Kerrouche N, Villemagne H. CalePso Study Team.Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of scalp psoriasis. Cutis. 2010; 85:43–50.

25. Reygagne P, Poncet M, Sidou F, Soto P. Clobetasol propionate shampoo 0.05% in the treatment of seborrheic dermatitis of the scalp: results of a pilot study. Cutis. 2007; 79:397–403.

26. Ortonne JP, Nikkels AF, Reich K, Ponce Olivera RM, Lee JH, Kerrouche N, Sidou F, Faergemann J. Efficacious and safe management of moderate to severe scalp seborrhoeic dermatitis using clobetasol propionate shampoo 0·05% combined with ketoconazole shampoo 2%: a randomized, controlled study. Br J Dermatol. 2011; 165:171–176.

27. Kim YR, Kim JH, Shin HJ, Choe YB, Ahn KJ, Lee YW. Clinical evaluation of a new-formula shampoo for scalp seborrheic dermatitis containing extract of Rosa centifolia petals and epigallocatechin gallate: a randomized, double-blind, controlled study. Ann Dermatol. 2014; 26:733–738.

28. Squire RA, Goode K. A randomised, single-blind, single-centre clinical trial to evaluate comparative clinical efficacy of shampoos containing ciclopirox olamine (1.5%) and salicylic acid (3%), or ketoconazole (2%, Nizoral) for the treatment of dandruff/seborrhoeic dermatitis. J Dermatolog Treat. 2002; 13:51–60.

29. Katsambas A, Antoniou C, Frangouli E, Avgerinou G, Michailidis D, Stratigos J. A double-blind trial of treatment of seborrhoeic dermatitis with 2% ketoconazole cream compared with 1% hydrocortisone cream. Br J Dermatol. 1989; 121:353–357.

30. Elewski B, Ling MR, Phillips TJ. Efficacy and safety of a new once-daily topical ketoconazole 2% gel in the treatment of seborrheic dermatitis: a phase III trial. J Drugs Dermatol. 2006; 5:646–650.

31. Dupuy P, Maurette C, Amoric JC, Chosidow O. Study Investigator Group. Randomized, placebo-controlled, double-blind study on clinical efficacy of ciclopiroxolamine 1% cream in facial seborrhoeic dermatitis. Br J Dermatol. 2001; 144:1033–1037.

32. Goldust M, Ranjkesh MR, Amirinia M, Golforoushan F, Rezaee E, Rezazadeh Saatlou MA. Sertaconazole 2% cream versus hydrocortisone 1% cream in the treatment of seborrheic dermatitis. J Dermatolog Treat. 2013; 02. 24. [Epub]. DOI: 10.3109/09546634.2013.782384.

33. Youn HJ, Kim SY, Park M, Jung WH, Lee YW, Choe YB, Ahn KJ. Efficacy and safety of cream containing climbazole/piroctone olamine for facial seborrheic dermatitis: a single-center, open-label split-face clinical study. Ann Dermatol. 2016; 28:733–739.

34. Berger TG, Duvic M, Van Voorhees AS, VanBeek MJ, Frieden IJ. American Academy of Dermatology Association Task Force. The use of topical calcineurin inhibitors in dermatology: safety concerns: report of the American Academy of Dermatology Association Task Force. J Am Acad Dermatol. 2006; 54:818–823.

35. Kastarinen H, Okokon EO, Verbeek JH. Topical anti-inflammatory agents for seborrheic dermatitis of the face or scalp: summary of a Cochrane Review. JAMA Dermatol. 2015; 151:221–222.

36. Kwon SH, Jeong MY, Park KC, Youn SW, Huh CH, Na JI. A new therapeutic option for facial seborrhoeic dermatitis: indole-3-acetic acid photodynamic therapy. J Eur Acad Dermatol Venereol. 2014; 28:94–99.

37. Schlesinger T, Rowland Powell C. Efficacy and safety of a low molecular weight hyaluronic Acid topical gel in the treatment of facial seborrheic dermatitis final report. J Clin Aesthet Dermatol. 2014; 7:15–18.

38. Fabbrocini G, Cantelli M, Monfrecola G. Topical nicotinamide for seborrheic dermatitis: an open randomized study. J Dermatolog Treat. 2014; 25:241–245.

39. Scaparro E, Quadri G, Virno G, Orifici C, Milani M. Evalua-tion of the efficacy and tolerability of oral terbinafine (Daskil) in patients with seborrhoeic dermatitis: a multicentre, ran-domized, investigator-blinded, placebo-controlled trial. Br J Dermatol. 2001; 144:854–857.

40. Geissler SE, Michelsen S, Plewig G. Very low dose isotretinoin is effective in controlling seborrhea. J Dtsch Dermatol Ges. 2003; 1:952–958.